Results 211 to 220 of about 62,912 (312)

Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 2, Page 210-223, February 2026.
Optimal treatment for frontal fibrosing alopecia (FFA) remains contentious. An international expert panel agreed that highly/ultra‐potent topical steroids were the preferred first‐line topical therapy. Preferred systemic therapies were 5‐alpha reductase inhibitors, followed by hydroxychloroquine.
Nekma Meah, Jane Li, Dmitri Wall, Katherine York, Bevin Bhoyrul, Laita Bokhari, Lachlan Coulthard, Leila Asfour, Leonardo Spagnol Abraham, Daniel Asz‐Sigall, Wilma F. Bergfeld, Regina C. Betz, Ulrike Blume‐Peytavi, Valerie Callender, Vijaya Chitreddy, Andrea Combalia, George Cotsarelis, Brittany Craiglow, Rachita Dhurat, Ncoza Dlova, Jeff Donovan, Andrei Doroshkevich, Samantha Eisman, Paul Farrant, Aida Gadzhigoroeva, Jack Green, Ramon Grimalt, Matthew Harries, Maria Hordinsky, Alan D. Irvine, Victoria Jolliffe, Spartak Kaiumov, Brett King, Steven Kossard, Joyce Lee, Won‐Soo Lee, Nino Lortkipanidze, Amy McMichael, Natasha Atanaskova Mesinkovska, Andrew Messenger, Paradi Mirmirani, Elise Olsen, Seth J. Orlow, Yuliya Ovcharenko, Bianca Maria Piraccini, Rodrigo Pirmez, Adriana Rakowska, Pascal Reygagne, Janet Roberts, Lidia Rudnicka, David Saceda‐Corralo, Jerry Shapiro, Pooja Sharma, Tatiana Silyuk, Poonkiat Suchonwanit, Anita Takwale, Antonella Tosti, W. I. Visser, Sergio Vañó‐Galván, Annika Vogt, Martin Wade, Leona Yip, Abraham Zlotogorski, Cheng Zhou, Rodney Sinclair   +64 more
wiley   +1 more source

Janus kinase and calcineurin‐inhibitor combination in anti‐MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile

Journal of Internal Medicine, Volume 299, Issue 2, Page 228-240, February 2026.
Abstract Objectives Anti‐MDA5 dermatomyositis (anti‐MDA5 DM) is the most severe subtype of dermatomyositis, due to its pulmonary involvement. Current treatment involves corticosteroids and immunosuppressants, but variability in responses exists. This study aims to evaluate the efficacy and safety of Janus kinase (JAK)– and calcineurin–inhibitor ...
Valentine Pagis, Quentin Astouati, Lucas Pacoureau, Yann Nguyen, Pierre Bay, Antoine Roux, Laure Gallay, Vincent Cottin, Benjamin Terrier, Alain Meyer, Charles Cerf, Mathilde Neuville, Baptiste Hervier, Arthur Renaud, Benoit Suzon, Nicolas Schleinitz, Thomas Papo, Pascaline Priou, Arsène Mekinian, Audrey Ullmer, Erwan Oehler, Noémie Gensous, Alice Berezne, Luc De Saint Martin, Thierry Marhadour, Mickaël Martin, Amélie Servettaz, Maxime Samson, Laurent Gilardin, Pierre Charles, Juliette Woessner, Thierry Carmoi, Baptiste Dilly, Wladimir Mauhin, Nicolas Baillet, Sébastien Humbert, Benjamin Thoreau, Marine Lemaitre, Claire Le Pendu, Pierre Loiseau, Thomas Quemeneur, Elodie Blanchard, Nicol Voermans, David Launay, Hilario Nunes, Olivier Benveniste, Yurdagul Uzunhan, Yves Allenbach   +47 more
wiley   +1 more source

448 Challenges of securing insurance approval for oral tofacitinib treatment of alopecia areata: A multi-institutional retrospective review [PDF]

, 2020
Sheena Desai, Kelly Lo, Vinod E. Nambudiri, Camila Villa, Avery LaChance, Ruth Ann Vleugels   +5 more
openalex   +1 more source

Comparative safety profiles of baricitinib and tofacitinib in the treatment of adult alopecia areata: a pharmacovigilance study based on the FAERS database. [PDF]

Front Public Health
Kong L, Liu X, Feng Y.
europepmc   +1 more source

Correction: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation [PDF]

, 2020
Tarik Alhmoud, Anas Gremida, Diego Colom Steele, Imaneh Fallahi, Wael Tuqan, Nina Nandy, Mahmoud Ismail, Barakat Aburajab Altamimi, Meng-Jun Xiong, Audra A. Kerwin   +9 more
openalex   +1 more source

Tofacitinib Use in a Patient With Rheumatoid Arthritis and Polycythemia Vera: A Case Report. [PDF]

Clin Case Rep
Bogojevic M, Medjedovic R, Markovic M, Bakic N, Pravilovic Lutovac D.   +4 more
europepmc   +1 more source

Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials. [PDF]

BMJ Open
Strand V, Schulze-Koops H, Al-Emadi S, Kinch CD, Gruben D, Germino R, Connell CA, Mysler E.   +7 more
europepmc   +1 more source

Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea

, 2022
Jianfeng Yu, Pengfei Li, Zhuang Li, Yingqi Li, Jiawei Luo, Wenru Su, Dan Liang   +6 more
openalex   +1 more source

REAL-WORLD EXPERIENCE WITH JANUS KINASE INHIBITORS IN EXTRAINTESTINAL MANIFESTATIONS AND INFLAMMATORY BOWEL DISEASE IN COLOMBIA: A COMPARATIVE STUDY (JAKEIM-IBD STUDY). [PDF]

Arq Gastroenterol
Parra-Izquierdo V, Ardila O, Márquez JR, Riveros J, Gómez-Venegas ÁA, Medrano-Almanza CA, Ballesteros M, Barreto-Pérez J, Frias-Ordoñez JS.   +8 more
europepmc   +1 more source

Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells [PDF]

, 2015
Barnes, PJ, Donnelly, LE, Fenwick, PS, Macedo, P   +3 more
core   +1 more source